According to broker Shore Capital, Poolbeg Pharma PLC (AIM: POLB) is making significant progress toward becoming a rare disease company.
Poolbeg Pharma plc (AIM:POLB) Interim results for the six months to 30 June 2024
Lead development candidate (POLB 001) on track with positive data demonstrating efficacy Independent research endorses potential US$10bn market opportunity for POLB 001 in cancer immunotherapy-induced CRS Patent portfolio significantly strengthened & expanded
Poolbeg Pharma (AIM:POLB) to Present at the H.C. Wainwright 26th Annual Global Investment Conference
27 August 2024 - Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that
Poolbeg Pharma PLC – Voluntary Delisting from OTCQB Market
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it is
Poolbeg Pharma PLC – Chief Executive Officer Jeremy Skillington PhD Talking To Zak Mir
Poolbeg Pharma Chief Executive Officer, Jeremy Skillington PhD present an overview of their current programmes and opportunities, focussing on POLB 001, data, exclusive option agreement and their AI-powered research using
Poolbeg Pharma PLC (AIM:POLB) Annual Report & AGM Notice
9 May 2024- Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, confirms that the
Poolbeg Pharma PLC (AIM:POLB) POLB 001 US Patent update
Continued expansion of IP portfolio enhancing protection of Poolbeg’s growing pipeline
Poolbeg Pharma PLC (AIM:POLB) Notice of Results
31 August 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, will announce